To Determine the Effect of KP-001 on Rosuvastatin, Caffeine PK and the Effect of Fluvoxamine on KP-001 PK in Volunteers

NCT ID: NCT06821698

Last Updated: 2025-09-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 38 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-02-13
• Study Completion Date: 2025-05-20

Brief Summary

Part 1 will evaluate the effects of KP-001 as an inhibitor of BCRP on the PK of rosuvastatin. In the Treatment Period 1, a single dose of rosuvastatin will be administered. In the Treatment Period 2, KP-001 will be administered once daily for 7 days and a single dose of rosuvastatin will be administered. Blood PK assessments of rosuvastatin will be performed until 48 hours postdose in each Treatment Period. Part 2 will evaluate the effects of KP-001 as an inducer and inhibitor of CYP1A2 on the PK of caffeine. A single dose of caffeine will be administered in the Treatment Period 1. KP-001 will be administered once daily for 10 days and a single dose of caffeine will be administered in the Treatment Period 2. Blood PK assessments of caffeine will be performed until 24 hours postdose in each Treatment Period. Part 3 will evaluate the effects of fluvoxamine as an inhibitor of CYP1A2 on the PK of KP-001. A single dose of KP-001 will be administered in the Treatment Period 1. Fluvoxamine will be administered as a single dose on the first day and then twice daily for 5 days and a single dose of KP-001 will be administered in the Treatment Period 2. Blood PK assessments of KP-001 will be performed until 48 hours postdose in each Treatment Period.

Conditions

Healty Volunteers

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

KP-001/Rosuvastatin calcium

Group Type: EXPERIMENTAL

KP-001

Intervention Type: DRUG

KP-001 100 mg dry syrup

Rosuvastatin calcium10mg

Intervention Type: DRUG

A oral dose of 10 mg tablet

KP-001/Caffeine citrate

Group Type: EXPERIMENTAL

KP-001

Intervention Type: DRUG

KP-001 100 mg dry syrup

Caffeine citrate

Intervention Type: DRUG

100 mg oral solution

KP-001/Fluvoxamine

Group Type: EXPERIMENTAL

KP-001

Intervention Type: DRUG

KP-001 100 mg dry syrup

Fluvoxamine

Intervention Type: DRUG

50 mg tablet

Interventions

KP-001

KP-001 100 mg dry syrup

Intervention Type: DRUG

Rosuvastatin calcium10mg

A oral dose of 10 mg tablet

Intervention Type: DRUG

Caffeine citrate

100 mg oral solution

Intervention Type: DRUG

Fluvoxamine

50 mg tablet

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. A participant who voluntarily agrees to participate in this study and signs an IRB-approved informed consent prior to performing any of the Screening Visit procedures.

2. A male or female participant who is between 18 to 55 years of age, inclusive, at the Screening Visit.

3. (Part 1 only) A participant who is non-Asian.

4. A female participant who is non-childbearing potential defined in Section 10.4 and not pregnant or breastfeeding.

5. A male participant who is sexually active with female partner(s) of childbearing potential must agree to use both a condom and spermicide from the first dose until 91 days after the last dose of KP-001.

6. A male participant who agrees not to donate sperm from the first dose until 91 days after the last dose of KP-001.

7. A continuous nonsmoker who has not used nicotine-containing products for at least 3 months prior to Day -1 of Treatment Period 1 and throughout the study, based on participant self-reporting and the result of cotinine test at screening and/or Day -1 of each Treatment Period.

8. A participant who is medically healthy with no clinically significant abnormal screening results (eg, medical history, physical examination, laboratory profiles, vital signs, or ECGs), in the opinion of the Investigator or designee. If screening and/or admission results are abnormal, they may be repeated once at screening and/or once at admission to confirm the participant's eligibility.

9. A participant who has body weight ≥ 50.0 kg and body mass index within the range 18.0 to 30.0 kg/m2, inclusive, at the Screening Visit.

Exclusion Criteria

1. A participant who is legally, mentally or physically incapacitated or, in the opinion of the Investigator, has significant mental or emotional problems, including psychiatric illness (eg, depression and/or anxiety) at the time of the Screening Visit, or that could reasonably be expected to develop during the conduct of the study.

2. A participant with significant history or clinical manifestation of any metabolic, allergic, dermatologic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder as determined by the Investigator or designee.

3. A participant with a history of any illness that, in the opinion of the Investigator or designee, might confound the results of the study or poses an additional risk to the participant by their participation in the study.

4. (For Part 3 only) A participant who meets any of the following criteria based on the C-SSRS assessment at screening:

1. Presence of suicidal ideation within the 6 months prior to screening (an answer of "yes" on Questions 1 or 2 of the C-SSRS Baseline/Screening version)

2. Any lifetime history of suicidal ideation (an answer of "yes" on Questions 4 or 5 of the C-SSRS Baseline/Screening version).

3. Any lifetime history of suicidal behavior as detected by the C-SSRS Baseline/Screening version.

5. A participant who used any prescription or non-prescription medications (including vitamins, recreational drugs, and dietary or herbal supplements) within 14 days or 5 half-lives (whichever is longer) prior to Day -1 of Treatment Period 1 and until completion of the Follow-up Call unless, in the opinion of the Investigator, may be treatment for an AE or will not interfere with the interpretation of safety or the PK assessments.

6. A participant who underwent blood donation or transfusion within 56 days prior to Day -1 of Treatment Period 1 and throughout the study.

7. A participant with a history or presence of hypersensitivity or idiosyncratic reaction to any components of the KP-001 formulation or any components of formulation used as study intervention during the study.

8. A participant with a history of drug or alcohol abuse (regular alcohol consumption exceeding 14 drinks/week [1 drink=5 ounces of wine, 12 ounces of beer, or 1.5 ounces of hard liquor]) within one year before the Screening Visit.

9. A participant who has enrolled in any clinical study of KP-001.

10. A participant with a complication of drug allergies or a history of drug allergies.

11. A participant who used any investigational drug in the last 30 days or 5 half-lives (if known), whichever is longer, prior to Day -1 of Treatment Period 1.

12. A participant who had any major illness within 30 days before the Screening Visit.

13. A participant who had any major surgical procedure within 30 days prior to Day -1 of Treatment Period 1 or any planned surgery during the study period.

14. A participant who had any laboratory abnormality that, in the judgment of the Investigator, would put the participant at unacceptable risk for participation in the study or may interfere with the assessments included in the study.

15. A participant with abnormal findings on the screening ECG deemed clinically significant by the Investigator or qualified designee.

16. A participant who is an employee of the Sponsor or any CRO involved in the study, the Investigator, or an immediate family member (partner, offspring, parents, siblings, or sibling's offspring) of an employee involved in the study.

17. (Part 2) A participant who has consumed alcohol- or caffeine-containing foods and beverages (eg, coffee, tea, cola, soda, cocoa, chocolate, and energy drink) within 72 hours prior to Day -1 of Treatment Period 1 and does not agree to refrain from consuming during the entire study. (Parts 1 and 3) A participant who has consumed alcohol- or caffeine-containing foods and beverages (eg, coffee, tea, cola, soda, cocoa, chocolate, and energy drink) within 72 hours prior to Day -1 of Treatment Period 1 and does not agree to refrain from consuming during the entire study, unless deemed acceptable by the Investigator.

18. A participant with positive urine drug or urine alcohol and positive cotinine test results at screening or Day -1 of Treatment Period 1.

19. A participant who has consumed grapefruit-containing foods and beverages within 7 days prior to Day -1 of Treatment Period 1 and does not agree to refrain from consuming during the entire study.

20. A participant who has consumed St. John's wort-containing foods and beverages within 14 days prior to Day -1 of Treatment Period 1 and does not agree to refrain from consuming during the entire study.

21. A participant who is unable or unwilling to undergo multiple venipunctures.

22. A participant with a history or presence of liver disease or cholecystectomy within one year prior to screening.

23. A participant with an HbA1c >5.7% at screening.

24. A participant with positive results at screening for human immunodeficiency virus, hepatitis B core antibody, hepatitis B surface antigen or hepatitis C virus.

25. A participant with a disorder or any condition that would interfere with the absorption, distribution, metabolism, or excretion of drugs.

26. A participant with an eGFR calculated using the CKD-EPI formula <80 mL/min at screening.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Kaken Pharmaceutical

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Parexel International Early Phase Clinical Unit

Glendale, California, United States

Countries

United States

Other Identifiers

KP-001-106

Identifier Type: -

Identifier Source: org_study_id